Eliem Therapeutics, a clinical stage biotech company generating therapies for pain, depression and other nervous-system related conditions, has filed to go public via an IPO. The company’s filing with the U.S. Securities and Exchange Commission comes on the heels of two rounds of private funding already this year tallying $140 million, including a $60 million Series B round in May. The Redmond, Wash.-based company was founded in 2019 and plans to list on the Nasdaq under the symbol ELYM. It aims to raise up to $80 million with the IPO.